UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2025 Neurogene Inc. (Exact name of registrant as specified in its charter) 535 W 24 Street, 5 Floor th th New York, NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (877) 237-5020 N/A (Former Name or Former Address, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-36327 Neurogene Inc. __________________________________ (Exact name of registrant as specified in its charter) (State ...

纳斯达克生物科技指数收涨1.56%。 成分股Sutro Biopharma收涨20.04%，Mersana Therapeutics涨17.19%，Neurogene涨15.12%。 Tempus AI收跌4.83%表现倒数第四，Prothena Plc.跌5.06%，Grail跌6.28%，OmniAb跌8.11%。 | | | NASDAQ Biotechnology | 4,260.4 +65.2 (+1.56%) | | | | | | | 4 ★ | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 ~ | | | 賠製 ▲ | 램물 ~ | 磨假~ | 涨跌幅 ▼ | 交易量 ▼ | 看涨 P | 时间 ~ | | F | M | Sutro Biopharma | | 1.050 | 1.080 | 0.832 | +20.04% | 2.92M | 印刷 | 03:59:59 G | | 日 | MI | Mersana Therapeutics | | 0.433 | 0.442 | 0.35 ...

V NEUROGENE Corporate Presentation March 2025 Disclaimer Forward Looking Statements This communication contains fowards-facking statements within the mecring of the Private Securities Lifiantion Reloam Act of 1995. These stolenents mov discuss and ex sults of operations or linancial condition, or otherwise, based on current expectations and belels of the management of Neurogene, as well as asumplions made by, and inform Newsocene, including, but not limited to stobernents recording the theropeulic podential ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 10-K __________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR Commission file number 001-36327 __________________________________ Neurogene Inc. __________________________________ (Exact name of registrant as specified in its charter) (State or other jurisdic ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Neurogene and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 11, 2024, N ...

UNITED STATES __________________________________________________ __________________________________________________ __________________________________________________ __________________________________ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For th ...

Financial Performance - Neurogene reported a net loss of $20.2 million for Q3 2024, compared to a net loss of $14.6 million in Q3 2023, reflecting an increase in operating expenses[10]. - General and Administrative (G&A) expenses increased to $5.9 million in Q3 2024 from $3.6 million in Q3 2023, driven by higher employee-related expenses[10]. - Neurogene's total assets decreased to $164.1 million as of September 30, 2024, from $222.6 million as of December 31, 2023[16]. Research and Development - Research and Development (R&D) expenses rose to $16.3 million in Q3 2024, up from $11.6 million in Q3 2023, primarily due to increased clinical trial costs for NGN-401[10]. - Interim clinical data from the NGN-401 trial showed improvements of 28% to 52% on the Rett Syndrome Behavioral Questionnaire (RSBQ) among participants[5]. - Neurogene plans to provide an update on the registrational trial design for NGN-401 in the first half of 2025[3]. - The FDA has allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose of NGN-401 after reviewing safety data[3]. - Neurogene completed enrollment of 6 participants in the NGN-101 gene therapy trial for CLN5 Batten disease but does not plan to move forward with the program due to a denied RMAT application[6]. - The company expects to announce additional interim Phase 1/2 clinical data for NGN-401 in the second half of 2025[5]. Cash Position - Cash, cash equivalents, and investments as of September 30, 2024, were $139.0 million, with an oversubscribed private placement raising approximately $200 million, extending the cash runway into the second half of 2027[9].

Neurogene NASDAQ: NGNE stock just took a sharp dive, plummeting 44% in a single day. Neurogene TodayNGNENeurogene$39.66 -0.34 (-0.85%) 52-Week Range$12.49▼$74.49Price Target$63.33Add to WatchlistBad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading, and they continued to slide through Tuesday. So, what was it that sent shares of Neurogene, a stock that was up 269% year-to-date, plummeting? And more importantly, is all hope lost for this clinical-stage biotec ...

On Monday, Neurogene Inc. NGNE released interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial of NGN-401 gene therapy for female pediatric patients with Rett syndrome, a rare genetic neurological and developmental disorder.Low-dose (1E15 vg) and high-dose (3E15 vg) NGN-401 have been well-tolerated with a favorable safety profile in the first seven pediatric participants (N=5 low-dose; N=2 high-dose):No treatment-related serious adverse events ( ...